Müller glia (MG) are major retinal supporting cells that participate in retinal metabolism, function, maintenance, and protection. During the pathogenesis of diabetic retinopathy (DR), a neurovascular disease and a leading cause of blindness, MG modulate vascular function and neuronal integrity by regulating the production of angiogenic and trophic factors. In this article, I will (1) briefly summarize our work on delineating the role and mechanism of MG-modulated vascular function through the production of vascular endothelial growth factor (VEGF) and on investigating VEGF signaling-mediated MG viability and neural protection in diabetic animal models, (2) explore the relationship among VEGF and neurotrophins in protecting Müller cells in in vitro models of diabetes and hypoxia and its potential implication to neuroprotection in DR and hypoxic retinal diseases, and (3) discuss the relevance of our work to the effectiveness and safety of long-term anti-VEGF therapies, a widely used strategy to combat DR, diabetic macular edema, neovascular age-related macular degeneration, retinopathy of prematurity, and other hypoxic retinal vascular disorders.
Introduction
Müller glia (MG), the major macroglia in the retina, extend from ganglion cell layer (GCL) to photoreceptor inner segment area and are surrounded by neurons in a highly organized manner (Jeon, Strettoi, & Masland, 1998) . This cellular localization is designed for MG to play major supporting roles in physiological and pathological responses, including retinal metabolism, function, maintenance, and protection by responding to stresses, providing trophic factors, removing metabolic wastes, controlling extracellular space volumes and ion and water homeostasis, participating visual cycles, releasing neurotransmitters, modulating vascular function, and regulating innate immunity (for review, see Reichenbach & Bringmann, 2013) . During the progression of diabetic retinopathy (DR), a neurovascular disease and a leading cause of blindness, MG play a key role in developing a wide range of pathological characteristics, which was reviewed extensively in this DR Special Edition (Coughlin et al., 2017) . MG regulate retinal inflammation, neovascularization, and vascular leakage and lesion, key DR-associated pathological features by producing a major angiogenic factor, vascular endothelial growth factor (VEGF or VEGF-A). On the other hand, VEGF signaling is critical to MG viability under hypoxic and diabetic conditions, which in turn, provides necessary protection to neurons in DR. In this article, I will 1) summarize our work on delineating the role and mechanism of MGmodulated vascular function through the production of VEGF and on investigating VEGF signaling regulated MG viability and neuroprotection in diabetic animal models, 2) explore the relationship among VEGF and neurotrophins in protecting Müller cells (MCs) with in vitro models of diabetes and hypoxia and its potential implication for neuroprotection in DR and hypoxic retinal vascular diseases, and 3) discuss the relevance of our work to the effectiveness and safety of long-term anti-VEGF therapies, a widely used strategy to combat DR, diabetic macular edema (DME), neovascular age-related macular degeneration (AMD), retinopathy of prematurity (ROP), and other hypoxic retinal vascular disorders. 
